and cisplatin (P) yielded an objective response rate of 25% and a subjective response rate of 50% in patients with mesothelioma. In human mesothelioma cell
Combining different phases in the development of medical treatments within a single trial
β Scribed by Peter Bauer; Meinhard Kieser
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 154 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0277-6715
No coin nor oath required. For personal study only.
β¦ Synopsis
In the development of medical treatments, identi"cation of promising therapies and inference on selected treatments are usually performed in subsequent separate trials. An adaptive two-stage design is proposed for the situation of multiple treatments to be compared with a control, allowing integration of both steps within a single con"rmatory trial controlling the multiple level . After the interim analysis, the trial may be terminated early or is continued with a second stage, where the set of treatments may be reduced due to lack of e$cacy or to safety problems. The procedure is highly #exible with respect to the distributional assumptions, stopping rules and selection criteria and allows a completely free recalculation of the sample size for the second stage. Simulations show that the method may be substantially more powerful than classical one-stage multiple treatment designs with the same total sample size. As in conventional strategies with a series of separate experiments, a reasonable selection strategy has to be applied in order to prevent proceeding with non-optimal treatments.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as firstβline treatment in metastatic colorectal carcinoma (CRC). ## METHODS A total of 140 patients received capecitabine at a dose of 1
## Abstract ## BACKGROUND The treatment of patients with hepatocellular carcinoma (HCC) presents a major challenge, because associated cirrhosis limits the choice of chemotherapeutic agents. However, the abundant vascularity of HCC presents an attractive target for antiangiogenic therapy that pote